RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:529852

Combined hepatocellular carcinoma and cholangiocarcinoma

low confidenceDisorder

Also known as: Combined HCC-CC · Combined hepatocellular-cholangiocarcinoma · Hepatocholangiocarcinoma · cHCC-CC

Publications

2,223

Trials

5

Interventional, condition-specific

Researchers

1,177

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare hepatic tumor characterized by the presence of both hepatocytic and cholangiocytic differentiation within a primary liver carcinoma. The lesion commonly arises in the context of chronic liver disease (such as hepatitis B or C, or steatohepatitis) or exposure to a variety of exogenous agents. Patients may present with signs and symptoms related to the tumor, as well as to the underlying condition. Typical manifestations include right upper quadrant abdominal pain, weight loss, , jaundice, and ascites. The entity has been associated with a worse prognosis than hepatocellular carcinoma after resection.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

Cholangiohepatoma · Mixed hepatocellular cholangiocarcinoma · carcinoma of the liver and intrahepatic biliary tract · combined hepatocellular cancer and cholangiocarcinoma (bile duct cancer) · combined hepatocellular cancer and intrahepatic bile duct cancer (cholangiocarcinoma) · combined hepatocellular carcinoma and cholangiocarcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    2,223 matched papers (1,741 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    5 matched on ClinicalTrials.gov (4 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

2,223

2,223 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

2,223 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,741 in the last 10 years · low confidence

Phrase hits: 2,223 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,177

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang H10 papers · 2026

    Department of Pathology, Eastern Hepatobiliary Surgical Hospital, The Naval Medical University, Shanghai, China.

    Papers in Europe PMC
  2. 02
    Zhang L10 papers · 2026

    Clinical Laboratories, Shenyou Bio, Zhengzhou, China.

    Papers in Europe PMC
  3. 03
    li Y8 papers · 2026

    Research & Development, SeekIn Inc., Shenzhen, China.

    Papers in Europe PMC
  4. 04
    Wang Y8 papers · 2026

    Department of Medical Ultrasound, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang West Road, Guangzhou, 510120, China. liuivy527@163.com.

    Papers in Europe PMC
  5. 05
    Zhang J8 papers · 2026

    Department of Radiology, Eastern Hepatobilliary Surgery Hospital, The Second Military Medical University, No. 225 Changhai Road Yangpu Area, Shanghai 200433, China.

    Papers in Europe PMC
  6. 06
    Zhang Y8 papers · 2026

    Zhejiang Cancer Hospital, Hangzhou 310022, China.

    Papers in Europe PMC
  7. 07
    Chen X7 papers · 2025

    Department of Radiology, Eastern Hepatobilliary Surgery Hospital, The Second Military Medical University, No. 225 Changhai Road Yangpu Area, Shanghai 200433, China.

    Papers in Europe PMC
  8. 08
    Wang X7 papers · 2026

    Ganzhou Institute of Medical Imaging, Ganzhou Key Laboratory of Medical Imaging and Artificial Intelligence, Department of Medical Imaging, Ganzhou People's Hospital, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, China.

    Papers in Europe PMC
  9. 09
    Chen Y5 papers · 2024

    Department of Intervention, Shenzhen Bao'an People's Hospital, Shenzhen, 518100, Guangdong, China.

    Papers in Europe PMC
  10. 10
    Cong WM5 papers · 2026

    Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, People's Republic of China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

5

interventional trials for this specific condition

5 interventional trials matched this specific condition name; 4 currently recruiting in our sample.

Data as of 27 July 2026

5 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 87.9th percentile).

low confidence · 87.9th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

5 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

6 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Combined hepatocellular carcinoma and cholangiocarcinoma" OR "Combined HCC-CC" OR "Combined hepatocellular-cholangiocarcinoma" OR "Hepatocholangiocarcinoma" OR "cHCC-CC" OR "Cholangiohepatoma" OR "Mixed hepatocellular cholangiocarcinoma" OR "carcinoma of the liver and intrahepatic biliary tract" OR "carcinoma of liver and intrahepatic biliary tract" OR "combined hepatocellular cancer and cholangiocarcinoma (bile duct cancer)" OR "combined hepatocellular cancer and intrahepatic bile duct cancer (cholangiocarcinoma)"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Combined hepatocellular carcinoma and cholangiocarcinoma" OR "Combined HCC-CC" OR "Combined hepatocellular-cholangiocarcinoma" OR "Hepatocholangiocarcinoma" OR "cHCC-CC" OR "Cholangiohepatoma" OR "Mixed hepatocellular cholangiocarcinoma" OR "carcinoma of the liver and intrahepatic biliary tract" OR "carcinoma of liver and intrahepatic biliary tract" OR "combined hepatocellular cancer and cholangiocarcinoma (bile duct cancer)" OR "combined hepatocellular cancer and intrahepatic bile duct cancer (cholangiocarcinoma)"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 5 interventional · 6 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2223) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T18:07:12.144Z